IGLL1 Gene Agammaglobulinemia Type 2 Autosomal Recessive Genetic Test in UAE | 2800 AED

Executive Summary & Core Metrics

✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing

🚑 VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — Available daily from 8 AM to 11 PM

📞 Clinical Guidance: Complimentary post-test telephonic result interpretation with a genetic counsellor

📋 Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731

Test Overview & Methodology

The IGLL1 NGS test identifies pathogenic variants in the immunoglobulin lambda-like polypeptide 1 gene, confirming a diagnosis of autosomal recessive agammaglobulinemia type 2—a severe primary immunodeficiency characterized by absent B cells and profound hypogammaglobulinemia. Our next-generation sequencing assay covers all coding exons and splice junctions with >500x mean depth, delivering a definitive molecular diagnosis within 3–4 weeks.

Feature	Our IGLL1 NGS Test	Closest Alternative (Sanger/Panel)
Precision	99.9% analytical sensitivity for SNVs/indels	~98% limited to targeted regions
Methodology	NGS (Next Generation Sequencing) with full gene coverage	Sanger sequencing of selected exons
Turnaround Time	3–4 Weeks	4–6 Weeks
Sample Types	Whole Blood, Extracted DNA, FTA Card (one drop)	Whole Blood only

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh — Consultant Medical Genetics, DHA Registration ID: 9294403

"As a medical geneticist, I emphasise that this test provides a definitive genetic aetiology, but clinical correlation with immunoglobulin levels and B-cell phenotyping is mandatory. A negative IGLL1 result does not exclude all causes of agammaglobulinemia; variants in BTK and other genes must be considered. I urge every family to undergo comprehensive genetic counselling before sampling, as outlined in UAE Federal Decree-Law No. 4 of 2016 on Medical Liability."

Advisory & Safety Notes

Do not discontinue any prescribed immunoglobulin replacement therapy or antibiotics without direct consultation with your treating physician. This test is a diagnostic aid and does not substitute for emergency medical care.

Exclusion Criteria & Emergency Red Flags

This test is not validated for diagnosis of acute infection or emergency setting.
Patients with current severe neutropenia or life-threatening sepsis should seek immediate emergency care.
Minors require explicit parental consent and a genetic counselling session per UAE Federal Law No. 4 of 2016.
If the patient has received allogeneic hematopoietic stem cell transplant within the last 6 months, donor DNA may confound results—please inform the lab before sampling.

Patient FAQ & Clinical Guidance

1. What exactly does the IGLL1 gene test detect?

This next-generation sequencing assay identifies pathogenic variants in the IGLL1 gene, which cause autosomal recessive agammaglobulinemia type 2—a condition marked by absent B cells and severe antibody deficiency since infancy.

2. How is the sample collected for this test?

A certified phlebotomist arrives at your home between 8 AM and 11 PM to draw a small amount of whole blood; you can also provide a DNA sample on an FTA card if preferred. For alternative sample matrices, please consult with our clinical team.

3. What happens after I receive my IGLL1 result?

A genetic counsellor will interpret your report in a complimentary telephonic session, explaining any identified variant and its implications for treatment and family planning. Further clinical management discussions should involve your immunologist.

UAE Regulatory & Data Privacy Adherence

Data Protection & Legal Compliance

All genetic data is handled in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent is obtained per Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic information remains confidential and is not shared without explicit written authorization.

Clinical & Logistical Metadata

Test Name	IGLL1 Gene Agammaglobulinemia Type 2 Autosomal Recessive Genetic Test
Price (AED)	2,800
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Whole Blood, Extracted DNA, FTA Card
Methodology Used	Next Generation Sequencing (NGS)
ICD-10-CM Code	D80.0
LOINC Code	94017-7
DHA Facility License & Address	License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE)